Dermira Prices Initial Public Offering

REDWOOD CITY, Calif., October 2, 2014 – Dermira, Inc. (NASDAQ: DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today announced the pricing of its initial public offering of 7,812,500 shares of common stock at a price to the public of $16.00 per share. The shares are expected to begin trading on The NASDAQ Global Select Market on October 3, 2014 under the symbol DERM. In addition, Dermira has granted the underwriters a 30 day option to purchase up to an additional 1,171,875 shares of common stock to cover over-allotments, if any. Concurrently with the offering, Dermira is also selling through a private placement 468,750 shares of its common stock to UCB S.A., an existing stockholder, at the initial public offering price.

Citigroup and Leerink Partners are acting as joint book-running managers for the offering. Guggenheim Securities and Needham & Company are acting as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 2, 2014. This offering is being made solely by means of a prospectus, copies of which, when available, may be obtained from Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at [email protected], or by telephone at 1-800-831-9146, or Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by email at [email protected], or by telephone at 1‐800‐808‐7525, ext. 6142.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Dermira Contact
Andrew Guggenhime
Chief Operating Officer and Chief Financial Officer

Investor Contact
Westwicke Partners
Robert H. Uhl
Managing Director
[email protected]

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.